Figure 1626

Data from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) evaluating the effects of alternate-day steroids on graft survival. Patients receiving alternate-day steroids at 12 months were compared with those receiving daily steroids. The NAPRTCS found that the survival of living donor (panel A) and cadaveric (panel B) grafts subsequent to 12 months did not differ between the steroid treatment groups. Because a number of factors contribute to graft survival and the patients were not randomly delegated to steroid treatment groups, a proportional hazards regression model for graft survival after 12 months also was developed. Again, the use of alternate-day steroids had no adverse effect on graft survival for recipients of either living or cadaveric donor grafts. (From Jabs and coworkers [27]; with permission.)

0 0

Post a comment